Acceleron Pharma Inc. (XLRN)
XLRNPrice: $178.75
Fair Value: 🔒
🔒score
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company al... more
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and comme... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Habib Dable |
| IPO Date | 2013-09-18 | CAGR | 0.02% |
| Employees | 312 | Website | www.acceleronpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
XLRN chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.17B | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 11.87 |
| P/CF Ratio | -77.9 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 6.39% | Gross Margin | 1% |
| Operating Margin | -1.81% | Profit Margin | -1.79% |
| ROE | -0.25% | ROA | -0.18% |
| ROCE | -0.19% | Current Ratio | 14.85 |
| Quick Ratio | 14.85 | Cash Ratio | 11.15 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | — |